1. Signaling Pathways
  2. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  3. EGFR
  4. EGFR Inhibitors

EGFR Inhibitors

EGFR/ErbB1/HER1

ErbB2/HER2

ErbB3/HER3

ErbB4/HER4

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

EGFR Inhibitors, Antagonists & Activators
Product Name EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4 Purity
Osimertinib
EGFRL858R, IC50: 12 nM (Enzyme assays)
EGFRL858R/T790M, IC50: 1 nM (Enzyme assays)
      99.90%
Gefitinib
EGFR
      ≥98.0%
Trastuzumab  
HER2
    99.80%
Erlotinib
EGFR, IC50: 2 nM (Cell Free Assay)
      99.99%
Cetuximab
Soluble EGFR, Kd: 0.201 nM
EGFR, Kd: 0.147 nM (Fixed A431 cells)
      99.70%
Rezivertinib
EGFR
      99.93%
ASK120067
EGFRT790M, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 0.3 nM
EGFR (WT), IC50: 6 nM
EGFRExon 19 deletion, IC50: 0.5 nM
     
Afatinib
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
    99.72%
AG490
EGFR
      99.67%
Lapatinib
EGFR, IC50: 10.2 nM (Cell Free Assay)
ErbB2, IC50: 9.8 nM (Cell Free Assay)
    99.83%
Neratinib
EGFR, IC50: 92 nM
HER2, IC50: 59 nM
    ≥98.0%
Tucatinib  
HER2
    ≥99.0%
Genistein
EGFR, IC50: 0.6 μM (Cell Assay)
      99.68%
AG-1478
EGFR, IC50: 3 nM
      99.22%
Dacomitinib
EGFR, IC50: 6 nM
ErbB2, IC50: 45.7 nM
 
ErbB4, IC50: 73.7 nM
≥95.0%
Osimertinib mesylate
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 12 nM
      99.94%
Erlotinib Hydrochloride
EGFR, IC50: 2 nM
      99.99%
Pertuzumab  
HER2
    ≥99.1%
BI-4020
EGFRdel19 T790M C797S, IC50: 0.2 nM
EGFRdel19, IC50: 1 nM
EGFRWT, IC50: 190 nM
      ≥99.0%
Mobocertinib
EGFR (WT), IC50: 35 nM
      98.92%
Gefitinib hydrochloride
EGFR
      99.85%
Gefitinib-based PROTAC 3
EGFR, DC50: 11.7 nM (HCC827(exon 19 del) cells)
EGFR, DC50: 22.3 nM (H3255 (L858R mutantion) cells)
      99.98%
CUDC-101
EGFR, IC50: 2.4 nM
HER2, IC50: 15.7 nM
    99.19%
Sapitinib
EGFR, IC50: 4 nM
ErbB2, IC50: 3 nM
HER3, IC50: 4 nM
  99.99%
Pyrotinib
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
    99.61%
Afatinib dimaleate
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
    ≥95.0%
Lapatinib ditosylate
EGFR, IC50: 10.8 nM (Cell Free Assay)
ErbB2, IC50: 9.2 nM (Cell Free Assay)
    ≥98.0%
TAS6417
EGFR, IC50: 1.1-8.0 nM
      99.55%
NSC 228155
EGFR
      ≥98.0%
Pelitinib
EGFR, IC50: 38.5 nM
      98.80%
Mubritinib  
HER2, IC50: 6 nM
    99.97%
Lifirafenib
EGFR, IC50: 29 nM
EGFRL858R/T790M, IC50: 495 nM
      98.02%
TX1-85-1    
ErbB3, IC50: 23 nM
  ≥98.0%
Pyrotinib dimaleate
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
    99.63%
Rociletinib
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
      99.59%
Lazertinib
EGFRT790M
      99.73%
BMS-690514
EGFR, IC50: 5 nM
HER2, IC50: 20 nM
 
HER4, IC50: 60 nM
99.89%
Zorifertinib
EGFR, IC50: 0.3 nM
EGFRL858R, IC50: 0.2 nM
EGFRExon 19 deletion, IC50: 0.2 nM
      99.76%
AZ-5104
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 1 nM
EGFRL861Q, IC50: 6 nM
EGFR, IC50: 25 nM
   
ErbB4, IC50: 7 nM
99.92%
EAI045
EGFR, IC50: 1.9 μM
EGFRL858R, IC50: 0.019 μM
EGFRT790M, IC50: 0.19 μM
EGFRL858R/T790M, IC50: 0.002 μM
      98.90%
TAS0728
EGFR, IC50: 65 nM
HER2, IC50: 13 nM
Human HER2, IC50: 36 nM
 
HER4, IC50: 8.5 nM
99.53%
Canertinib
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
    99.82%
Icotinib
EGFR, IC50: 5 nM
      99.79%
BDTX-189
EGFR, Kd: 0.2 nM
HER2, Kd: 0.76 nM
    99.94%
PD168393
EGFR, IC50: 0.7 nM
      98.87%
Butein
EGFR, IC50: 16 μM (in HepG2 cells)
      99.95%
Daphnetin
EGFR, IC50: 7.67 μM
      99.21%
Tesevatinib
EGFR, IC50: 0.3 nM
ErbB2, IC50: 16 nM
    ≥98.0%
TAK-285
EGFR, IC50: 23 nM
HER2, IC50: 17 nM
    ≥95.0%
Olmutinib
EGFRExon 19 deletion, IC50: 9.2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 10 nM (Cell Assay)
      99.88%
Canertinib dihydrochloride
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
    ≥98.0%
EGFR-IN-7
EGFR (WT), IC50: 7.92 nM
EGFR (C797S/T790M/L858R), IC50: 0.218 nM
      99.76%
Nazartinib
EGFRL858R/T790M, Ki: 31 nM
      99.57%
Almonertinib
EGFRT790M, IC50: 0.37 nM
EGFRL858R/T790M, IC50: 0.29 nM
EGFRdel19 T790M, IC50: 0.21 nM
      99.84%
Varlitinib
HER1, IC50: 7 nM
HER2, IC50: 2 nM
 
HER4, IC50: 4 nM
≥98.0%
AEE788
EGFR, IC50: 2 nM
ErbB2, IC50: 6 nM
    ≥98.0%
PD153035
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
      99.24%
Chrysophanol
EGFR
      99.73%
Tarloxotinib bromide  
EGFR/HER2
    98.97%
Mobocertinib succinate
EGFR exon 20 insertion
HER2
    99.61%
Icotinib Hydrochloride
EGFR, IC50: 5 nM
      99.95%
Tyrphostin 23
EGFR, IC50: 35 μM (Cell Assay)
EGFR, Ki: 11 μM
      98.80%
PD158780
EGFR, IC50: 8 μM (Cell Assay)
ErbB2, IC50: 49 nM (Cell Assay)
ErbB3, IC50: 52 nM (Cell Assay)
ErbB4, IC50: 52 nM (Cell Assay)
99.52%
AST2818 mesylate
EGFR
      98.16%
CP-724714  
ErbB2, IC50: 10 nM
    99.33%
WZ4002
EGFRL858R, IC50: 2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 8 nM (Cell Assay)
EGFRE746_A750, IC50: 3 nM (Cell Assay)
EGFRE746_A750/T790M, IC50: 2 nM (Cell Assay)
      99.69%
WHI-P154
EGFR, IC50: 4 nM
      99.20%
Osimertinib dimesylate
EGFRL858R, IC50: 12 nM
EGFRL858R/T790M, IC50: 1 nM
      99.96%
Almonertinib hydrochloride
EGFRT790M, IC50: 0.37 nM
EGFRL858R/T790M, IC50: 0.29 mM
EGFRdel19 T790M, IC50: 0.214 nM
      98.03%
PD153035 Hydrochloride
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
      99.06%
AV-412
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.5 nM
EGFRT790M, IC50: 0.79 nM
EGFRL858R/T790M, IC50: 2.3 nM
ErbB2, IC50: 19 nM
    99.17%
Avitinib maleate
EGFR, IC50: 7.68 nM
      99.17%
Epertinib hydrochloride
EGFR, IC50: 1.48 nM
HER2, IC50: 7.15 nM
 
HER4, IC50: 2.49 nM
99.76%
Allitinib tosylate
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM
 
ErbB4, IC50: 0.8 nM
99.23%
Tarlox-TKI
EGFR
      99.33%
RG14620
EGFR, IC50: 3 μM (Cell Assay)
      99.85%
WHI-P180
EGFR, IC50: 4 μM
      99.76%
(Rac)-JBJ-04-125-02
EGFR (L858R/T790M), IC50: 0.26 nM
      ≥95.0%
AV-412 free base
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.51 nM
EGFRL858R/T790M, IC50: 2.3 nM
EGFRT790M, IC50: 0.79 nM
ErbB2, IC50: 19 nM
    98.07%
EGFR-IN-12
EGFR (WT), IC50: 21 nM
EGFRL858R, IC50: 63 nM
EGFRL861Q, IC50: 4 nM
   
HER4, IC50: 7640 nM
99.49%
Tyrphostin AG 528
EGFR, IC50: 4.9 μM
ErbB2, IC50: 2.1 μM
    ≥98.0%
Falnidamol
EGFR, IC50: 3 nM
ErbB2, IC50: 3.4 μM
    98.07%
Naquotinib mesylate
EGFRL858R/T790M
EGFRL858R
EGFRExon 19 deletion
EGFRExon 19 deletion/T790M
EGFR, IC50: 230 nM
      98.02%
MTX-211
EGFR
      ≥98.0%
Astragaloside VI
EGFR
      ≥98.0%
Rociletinib hydrobromide
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
      97.45%
CL-387785
EGFR, IC50: 370 pM
      98.10%
Mutated EGFR-IN-1
EGFRL858R
EGFRExon 19 deletion/T790M
EGFRT790M
      99.36%
Epertinib
EGFR, IC50: 1.48 nM
HER2, IC50: 2.49 nM
 
HER4, IC50: 7.15 nM
≥98.0%
Theliatinib
EGFR, IC50: 3 nM
EGFR, Ki: 0.05 nM
EGFR (L858R/T790M), IC50: 22 nM
      99.88%
AG-825
EGFR, IC50: 19 μM
ErbB2, IC50: 0.35 μM
    98.07%
PD-161570
EGFR, IC50: 240 nM
      99.04%
EGFR-IN-1 TFA
EGFRL858R/T790M
      99.05%
NRC-2694
EGFR
      99.71%
Naquotinib
EGFR, IC50: 230 nM
     
Mutated EGFR-IN-3
EGFRL858R/T790M, IC50: 12 nM
EGFRC797S, IC50: 13 nM
     
JBJ-04-125-02
EGFR (L858R/T790M), IC50: 0.26 nM
     
DBPR112
EGFRL858R/T790M, IC50: 48 nM
EGFRWT, IC50: 15 nM
      98.07%
EGFR-IN-1
EGFRL858R/T790M
     
EGFR/ErbB-2/ErbB-4 inhibitor-2
EGFR, IC50: 0.017 μM
ErbB2, IC50: 0.08 μM
 
ErbB4, IC50: 1.91 μM
99.69%
AG 555
EGFR
      ≥98.0%
ZM 449829
EGFR, pIC50: 5.0
     
AG-494
EGFR, IC50: 0.7 μM
      99.06%
Mutant EGFR inhibitor
EGFRL858R
EGFRExon 19 deletion
EGFRT790M
      99.10%
Simotinib
EGFR, IC50: 19.9 nM
     
Nazartinib mesylate
EGFRL858R/T790M, Ki: 31 nM
     
CNX-2006
EGFRT790M, IC50: 20 nM
      99.68%
ZD-4190
EGFR
      99.20%
BGB-102
EGFR, IC50: 9.6 nM
HER2, IC50: 18 nM
 
HER4, IC50: 40.3 nM
97.10%
Lapatinib ditosylate
EGFR, IC50: 10.8 nM
ErbB2, IC50: 9.2 nM
   
JBJ-02-112-05
EGFRL858R/T790M, IC50: 15 nM
     
EMI48
EGFRL858R/T790M/C797S
EGFRdel19 T790M C797S
      99.02%
Pertuzumab (PBS)  
HER2
   
(E)-AG 99
EGFR
      99.41%
Mutated EGFR-IN-2
EGFR (L858R/T790M), IC50: <1 nM
     
EGFR-IN-15
EGFR, IC50: 4 nM
     
EGFR-IN-1 hydrochloride
EGFRL858R/T790M
     
EMI56
EGFRL858R/T790M/C797S
EGFRdel19 T790M C797S
      99.72%
EGFR-IN-11
EGFRL858R/T790M/C797S, IC50: 18 nM
      99.81%
CHMFL-EGFR-202
EGFRT790M, IC50: 5.3 nM
EGFR, IC50: 8.3 nM
ErbB2, IC50: 8.1 nM
 
ErbB4, IC50: 3.2 nM
EGFR-IN-5
EGFR, IC50: 10.4 nM
EGFRL858R, IC50: 1.1 nM
EGFRL858R/T790M, IC50: 34 nM
EGFRL858R/T790M/C797S, IC50: 7.2 nM
     
SU5204  
HER2, IC50: 51.5 μM
    98.89%
Lavendustin C
EGFR, IC50: 0.012 μM
     
HKI-357
EGFR, IC50: 34 nM
ErbB2, IC50: 33 nM
    ≥99.0%
(E/Z)-CP-724714  
HER2
   
PD-089828
EGFR, IC50: 5.47 μM
EGFR, Ki: 3.16 μM
     
Simotinib hydrochloride
EGFR, pIC50: 19.9 nM
     
EGFR-IN-16
EGFR, pIC50: 4.85
HER2, pIC50: 4.74
   
EGFR-IN-9
EGFR (WT), IC50: 7 nM
EGFRL858R/T790M, IC50: 28 nM
     
EMI1
EGFRdel19 T790M C797S
EGFRL858R/T790M/C797S
     
AG-1478 hydrochloride
EGFR, IC50: 3 nM
     
CGP52411
EGFR, IC50: 0.3 μM
      99.82%
PF-6274484
EGFR (WT), Ki: 0.18 nM
EGFRL858R/T790M, Ki: 0.14 nM
     
WHI-P180 hydrochloride
EGFR, IC50: 4 μM
     
Erlotinib mesylate
EGFR, IC50: 2 nM
     
Allitinib
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM
 
ErbB4, IC50: 0.8 nM